JAMA:为全麻患者给予镇静剂遭到质疑

2015-03-04 崔倩译 MedSci原创

根据3月3日的JAMA发表的一项研究,虽然在术前经常使用镇静剂,但一项随机试验发现,那些在手术前接受镇静剂劳拉西泮全身麻醉手术患者,与安慰剂或无术前用药相比,手术后没有改善,但与较长时间直至清除出呼吸管(拔管)和早期的认知恢复率较低有关。 根据文章的背景资料,定于手术的患者可能会遇到相当大的压力和焦虑。术前服用苯二氮卓(一类镇静剂)经常用于减少焦虑,但也导致失忆,嗜睡,和认知功能障碍。治疗焦虑不

根据3月3日的JAMA发表的一项研究,虽然在术前经常使用镇静剂,但一项随机试验发现,那些在手术前接受镇静剂劳拉西泮全身麻醉手术患者,与安慰剂或无术前用药相比,手术后没有改善,但与较长时间直至清除出呼吸管(拔管)和早期的认知恢复率较低有关。

根据文章的背景资料,定于手术的患者可能会遇到相当大的压力和焦虑。术前服用苯二氮卓(一类镇静剂)经常用于减少焦虑,但也导致失忆,嗜睡,和认知功能障碍。治疗焦虑不一定有更好的围手术期(手术前后)相关的经验。更需要知道的是关于术前焦虑治疗的疗效,以更好地告知患者来做出明智的决定。

法国马赛的Hôpital de la Timone Adulte阿克塞尔莫里斯和同事随机指定了法国5所教学医院接受各种全身麻醉手术的1062例成人患者(年龄小于70岁),他们或是服用2.5毫克的劳拉西泮(术前2小时服用),安慰剂或无术前用药。围手术期病人的经验是在术后24小时以调查问卷的形式进行评估。

研究人员发现,与无术前用药或服用安慰剂相比,术前服用劳拉西泮并没有改善患者术前总体满意度。对焦虑最严重的患者来说,各组间总体满意度没有显著差异。

劳拉西泮组的拔管时间(17分钟)明显要比无术前用药(12分钟)和安慰剂组(13分钟)要长。麻醉结束40分钟后,劳拉西泮组患者恢复认知功能的比例(51%)明显低于无术前用药组(71%)及安慰剂组(64%)。术后1天,在围手术期失忆的患者明显比其他组数量要多。

“与安慰剂相比,劳拉西泮确实能够在术前减轻患者的焦虑。因为术前焦虑治疗没有整体的利益,患者在到达手术室前焦虑可能不会影响整体满意度,”作者写道。

“这些研究结果表明缺乏作为全麻患者术前服用劳拉西泮并无益处。”

原始出处

Axel Maurice-Szamburski, Pascal Auquier, Véronique Viarre-Oreal, Philippe Cuvillon, Michel Carles, Jacques Ripart, Stéphane Honore, Thibaut Triglia, Anderson Loundou, Marc Leone, Nicolas Bruder. Effect of Sedative Premedication on Patient Experience After General Anesthesia. JAMA, 2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=48002, encodeId=5858480027c, content=值得思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735059, encodeId=e6ef1e3505916, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri Sep 18 23:22:00 CST 2015, time=2015-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17878, encodeId=450f1e8784d, content=小问题也可做大课题,赞一个。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Sat Mar 07 17:31:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476533, encodeId=7dfc14e653387, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553440, encodeId=3c24155344029, content=<a href='/topic/show?id=eace96809ee' target=_blank style='color:#2F92EE;'>#镇静剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96809, encryptionId=eace96809ee, topicName=镇静剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad414379206, createdName=caoliehu, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17602, encodeId=7e0e1e602a3, content=值得参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Mar 04 21:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得思考

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=48002, encodeId=5858480027c, content=值得思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735059, encodeId=e6ef1e3505916, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri Sep 18 23:22:00 CST 2015, time=2015-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17878, encodeId=450f1e8784d, content=小问题也可做大课题,赞一个。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Sat Mar 07 17:31:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476533, encodeId=7dfc14e653387, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553440, encodeId=3c24155344029, content=<a href='/topic/show?id=eace96809ee' target=_blank style='color:#2F92EE;'>#镇静剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96809, encryptionId=eace96809ee, topicName=镇静剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad414379206, createdName=caoliehu, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17602, encodeId=7e0e1e602a3, content=值得参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Mar 04 21:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
    2015-09-18 saikp
  3. [GetPortalCommentsPageByObjectIdResponse(id=48002, encodeId=5858480027c, content=值得思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735059, encodeId=e6ef1e3505916, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri Sep 18 23:22:00 CST 2015, time=2015-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17878, encodeId=450f1e8784d, content=小问题也可做大课题,赞一个。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Sat Mar 07 17:31:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476533, encodeId=7dfc14e653387, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553440, encodeId=3c24155344029, content=<a href='/topic/show?id=eace96809ee' target=_blank style='color:#2F92EE;'>#镇静剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96809, encryptionId=eace96809ee, topicName=镇静剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad414379206, createdName=caoliehu, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17602, encodeId=7e0e1e602a3, content=值得参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Mar 04 21:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
    2015-03-07 tutu159

    小问题也可做大课题,赞一个。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=48002, encodeId=5858480027c, content=值得思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735059, encodeId=e6ef1e3505916, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri Sep 18 23:22:00 CST 2015, time=2015-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17878, encodeId=450f1e8784d, content=小问题也可做大课题,赞一个。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Sat Mar 07 17:31:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476533, encodeId=7dfc14e653387, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553440, encodeId=3c24155344029, content=<a href='/topic/show?id=eace96809ee' target=_blank style='color:#2F92EE;'>#镇静剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96809, encryptionId=eace96809ee, topicName=镇静剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad414379206, createdName=caoliehu, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17602, encodeId=7e0e1e602a3, content=值得参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Mar 04 21:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=48002, encodeId=5858480027c, content=值得思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735059, encodeId=e6ef1e3505916, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri Sep 18 23:22:00 CST 2015, time=2015-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17878, encodeId=450f1e8784d, content=小问题也可做大课题,赞一个。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Sat Mar 07 17:31:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476533, encodeId=7dfc14e653387, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553440, encodeId=3c24155344029, content=<a href='/topic/show?id=eace96809ee' target=_blank style='color:#2F92EE;'>#镇静剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96809, encryptionId=eace96809ee, topicName=镇静剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad414379206, createdName=caoliehu, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17602, encodeId=7e0e1e602a3, content=值得参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Mar 04 21:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=48002, encodeId=5858480027c, content=值得思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:22:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735059, encodeId=e6ef1e3505916, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Fri Sep 18 23:22:00 CST 2015, time=2015-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17878, encodeId=450f1e8784d, content=小问题也可做大课题,赞一个。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9c21612116, createdName=tutu159, createdTime=Sat Mar 07 17:31:00 CST 2015, time=2015-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476533, encodeId=7dfc14e653387, content=<a href='/topic/show?id=6ff229e7126' target=_blank style='color:#2F92EE;'>#全麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29771, encryptionId=6ff229e7126, topicName=全麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553440, encodeId=3c24155344029, content=<a href='/topic/show?id=eace96809ee' target=_blank style='color:#2F92EE;'>#镇静剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96809, encryptionId=eace96809ee, topicName=镇静剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad414379206, createdName=caoliehu, createdTime=Fri Mar 06 06:22:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17602, encodeId=7e0e1e602a3, content=值得参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Wed Mar 04 21:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
    2015-03-04 medcardio

    值得参考

    0

相关资讯

英专家呼吁控制使用镇静剂类药品

  英国部分医学专家和学者16日发表声明,呼吁控制镇静剂类药品的使用。   来自英国皇家全科医学院、皇家精神病学会以及全国滥用物品治疗署的专家说,需要加强控制苯并二氮杂(卓加草字头)类镇静剂类药物的使用,希望只是在特殊而且必要的情况下使用,并需定期复诊。声明还说,医患双方应在使用安眠药等镇静剂类药品前对服药期限达成共识。   这类药容易成瘾,会造成严重后果。这意味着数百万服用安眠药的英国人以后

JAMA:镇静剂可缩短ICU患者机械通气时间

3月21日,国际著名杂志《美国医学会杂志》JAMA上的一项研究披露,2个随机化的试验结果表明,在重症监护病房(ICU)内接受长时间机械通气的病人中,在维持轻度至中度的镇静时,使用镇静药右旋美托咪定的效果不比使用标准镇静剂咪达唑仑和异丙酚的效果差(即不比标准治疗的效果差);另外,右旋美托咪定与咪达唑仑相比可缩短机械通气的时间,与其它药物相比,改善了患者表达疼痛的能力。 人们假设,对ICU患者施